Lowell has been trying to reinvent itself for the better part of five decades. It turned its shuttered textile mills into a National Historical Park in the 1970s. It built the Hamilton Canal Innovation District on former industrial land. It launched the Lowell Innovation Network Corridor in partnership with UMass Lowell, a public-private project promising […]
When Kailera Therapeutics priced its IPO at $16 per share on Thursday evening, it was already doing something that hadn’t happened in the biotech sector in five years: raising $625 million in a single public market debut. When trading opened Friday morning on the Nasdaq Global Select Market, the stock climbed straight to $26 and
Boston’s biotech scene may be gearing up for another high-profile IPO moment—this time led by a company betting big on the future of depression treatment. Seaport Therapeutics, a relatively young but well-funded player based in the city’s Seaport district, is preparing to enter public markets with a clear mission: push its pipeline of neuropsychiatric drugs
A high-stakes legal clash is unfolding in Massachusetts’ offshore wind sector, putting one of the country’s most closely watched renewable energy projects under fresh scrutiny. Vineyard Wind, the developer behind a massive wind farm off the coast of Martha’s Vineyard, has filed a lawsuit in Boston aimed at stopping its turbine supplier from exiting the
Most cancer drugs that kill tumors also damage healthy tissue. That is not a flaw in the design — it is the fundamental problem that oncology has been trying to solve for decades. And it is the problem that Stipple Bio, a Cambridge-based biotechnology company that emerged from stealth this week with a heavily oversubscribed
The optimism lasted exactly one month. In February, the Massachusetts Business Confidence Index had crossed the line separating pessimism from optimism for the first time in a year—a small but significant respite for the state’s employers after months of mounting uncertainty. In March, that relief vanished. The AIM Business Confidence Index, the longest-running barometer of
Cambridge-based Biogen announced it will acquire Apellis Pharmaceuticals, headquartered in Waltham, in an all-cash deal worth approximately $5.6 billion — or $41 per share. When Apellis stock closed on Monday, it was trading at roughly half that. By Tuesday morning, shares had more than doubled overnight. That kind of move tells you something about what
There is a pattern worth naming here. In 2024, Takeda announced a major restructuring that cut hundreds of Massachusetts jobs. In 2025, the Japanese pharmaceutical giant eliminated more Cambridge positions after shutting down its cell therapy program entirely. And this week, the company filed a WARN Act notice with the state of Massachusetts confirming that
Takeda Is Cutting 250 Jobs in Cambridge. It’s the Third Time in Two Years Read More »
There is a 14-story office building at 1 State Street, in the heart of Boston’s Financial District, that has been quietly emptying out for years. It sits one block from Faneuil Hall, two blocks from the waterfront, steps from three MBTA lines. By almost any measure, it is exactly where people should want to live.
Boston’s Empty Office Buildings Are Becoming Apartments. 1 State Street Is Next Read More »
Fifty million dollars is a serious amount of money for a company that started as a vaccine project in Harvard’s Innovation Lab. But then again, Ozempic is a serious amount of market — and Terrestrial Bio, the Boston-based company that just closed a $50 million Series C round, is betting it has figured out something
